BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 16474835)

  • 1. Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Gallina A; SaccĂ  A; Montorsi P; Rigatti P; Montorsi F
    Nat Clin Pract Urol; 2005 May; 2(5):239-47. PubMed ID: 16474835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
    Gresser U; Gleiter CH
    Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
    World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging oral drugs for erectile dysfunction.
    Briganti A; Salonia A; Gallina A; Suardi N; Rigatti P; Montorsi F
    Expert Opin Emerg Drugs; 2004 May; 9(1):179-89. PubMed ID: 15155143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
    Vickers MA; Satyanarayana R
    Int J Impot Res; 2002 Dec; 14(6):466-71. PubMed ID: 12494279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
    Chen Q; Wang N; Yao F; Lu X
    Zhonghua Nan Ke Xue; 2004 Apr; 10(4):302-4. PubMed ID: 15148932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients.
    Weeks JL; Zoraghi R; Beasley A; Sekhar KR; Francis SH; Corbin JD
    Int J Impot Res; 2005; 17(1):5-9. PubMed ID: 15538396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
    Rosen RC; McKenna KE
    Annu Rev Sex Res; 2002; 13():36-88. PubMed ID: 12836729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction.
    Mulhall JP; Montorsi F
    Eur Urol; 2006 Jan; 49(1):30-7. PubMed ID: 16263207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
    Kloner RA
    Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Levitra (vardenafil)--a new PDE 5 inhibitor for the treatment of erectile dysfunction].
    Katsarov M
    Akush Ginekol (Sofiia); 2004; 43 Suppl 1():31-2. PubMed ID: 15323315
    [No Abstract]   [Full Text] [Related]  

  • 13. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
    Gupta M; Kovar A; Meibohm B
    J Clin Pharmacol; 2005 Sep; 45(9):987-1003. PubMed ID: 16100293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey.
    Kim NN
    Int J Impot Res; 2003 Oct; 15 Suppl 5():S13-9. PubMed ID: 14551572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vardenafil treatment for erectile dysfunction.
    Crowe SM; Streetman DS
    Ann Pharmacother; 2004 Jan; 38(1):77-85. PubMed ID: 14742800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDE-5 inhibitors: current status and future trends.
    Masson P; Lambert SM; Brown M; Shabsigh R
    Urol Clin North Am; 2005 Nov; 32(4):511-25, viii. PubMed ID: 16291042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
    Ströberg P; Hedelin H; Ljunggren C
    Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tadalafil and vardenafil.
    Neumeyer K; Kirkpatrick P
    Nat Rev Drug Discov; 2004 Apr; 3(4):295-6. PubMed ID: 15124623
    [No Abstract]   [Full Text] [Related]  

  • 19. PDE5 inhibitors: are there differences?
    Carson CC
    Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vardenafil Bayer Yakuhin.
    Sommer F; Engelmann U
    Curr Opin Investig Drugs; 2002 Apr; 3(4):607-13. PubMed ID: 12090732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.